Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | PTPRB | P23467 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | OGG1 | O15527 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18308818 | 0.86 | ACHE (0.35) | — | |
| SCHEMBL20032691 | 0.85 | HDAC1 (0.33) | TUBB1 | |
| SCHEMBL13863673 | 0.80 | SOS1 (0.33) | — | |
| SCHEMBL7793453 | 0.75 | SMN1; SMN2 (0.39) | TUBB1HPGDCYP3A4TDP1GPR84 | |
| SCHEMBL10027422 | 0.74 | HDAC1 (0.41) | — | |
| SCHEMBL13863674 | 0.74 | RXRA (0.30) | — | |
| SCHEMBL13863675 | 0.74 | — | — | |
| SCHEMBL2633660 | 0.73 | ALDH1A1 (0.59) | TUBB1HPGDCYP3A4FFAR4TDP1 | |
| SCHEMBL13863676 | 0.71 | FFAR4 (0.36) | CYP3A4FFAR4 | |
| SCHEMBL3021181 | 0.71 | TUBB1 (0.35) | TUBB1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795398-B2 | Liquid-crystalline medium and liquid-crystal display comprising the same and compounds | MERCK PATENT GMBH (DE) | 2023-10-24 | — | — | US | disclosed |
| US-20230323207-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2023-10-12 | — | — | US | disclosed |
| US-11739266-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2023-08-29 | — | — | US | disclosed |
| US-11718791-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2023-08-08 | — | — | US | disclosed |
| US-11685863-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2023-06-27 | — | — | US | disclosed |
| US-11667841-B2 | Dibenzofuran and dibenzothiophene derivatives | MERCK PATENT GMBH (DE) | 2023-06-06 | — | — | US | disclosed |
| US-20180195002-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-07-12 | — | — | US | disclosed |
| US-20180187080-A1 | LIQUID CRYSTAL MEDIUM CONTAINING POLYMERISABLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2018-07-05 | — | — | US | disclosed |
| US-20180179446-A1 | LIQUID CRYSTAL MEDIUM CONTAINING POLYMERISABLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2018-06-28 | — | — | US | disclosed |
| US-20180163134-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2018-06-14 | — | — | US | disclosed |
| US-7618554-B2 | for in-plane switching (IPS) liquid crystal displays and low voltage-driven twist nematic (TN) liquid crystal displays and has a high dielectric anisotropy and a low rotational viscosity; perfluoroallyl difluorophenyl ethers | ADEKA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20090247620-A1 | Benzochromene Derivatives for Use in Liquid Crystal Media and as Therapeutic Active Substances | MERCK PATENT GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
| US-20090201457-A1 | LIQUID-CRYSTALLINE MIXTURES AND LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GESELLSCHAFT (DE) | 2009-08-13 | — | — | US | disclosed |
| US-7563491-B2 | Liquid crystalline medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2009-07-21 | — | — | US | disclosed |
| US-7531106-B2 | Mesogenic compounds, medium for electro-optical displays and electro-optical display | MERCK PATENT GMBH (DE) | 2009-05-12 | — | — | US | disclosed |
| US-7482044-B2 | Liquid crystalline medium and liquid crystal display | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2009-01-27 | — | — | US | disclosed |
| US-7445819-B2 | Liquid crystalline medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2008-11-04 | — | — | US | disclosed |
| US-20080149890-A1 | Liquid Crystal Composition | ADEKA CORPORATION (JP) | 2008-06-26 | — | — | US | disclosed |
| US-20080124492-A1 | Liquid crystalline medium and liquid crystal display | MERCK PATENT GMBH | 2008-05-29 | — | — | US | disclosed |
| US-20070235688-A1 | Liquid crystalline medium and liquid crystal display | MERCK PATENT GESELLSCHAFT | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718791-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | VCL, ILK, LCP1 | TUBB1 2610/4885HPGD 3819/4885CYP3A4 1699/4885 |
| US-11685863-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | LPXN, VCL, LCP1 | TUBB1 2503/4885HPGD 3671/4885CYP3A4 3367/4885 |
| US-11667841-B2 | Dibenzofuran and dibenzothiophene derivatives | DDT, MYT1, DBF4 | TUBB1 392/4885HPGD 2923/4885CYP3A4 831/4885 |
| US-20090247620-A1 | Benzochromene Derivatives for Use in Liquid Crystal Media and as Therapeutic Active Substances | LPO, SBDS, OCIAD1 | TUBB1 565/4885HPGD 824/4885CYP3A4 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.